AI Article Synopsis
- Myelopathy is increasingly identified as a symptom of various antibody-mediated neuroinflammatory disorders.
- While some autoimmune myelopathies, like NMOSD and MOGAD, are well understood, others such as Hu/ANNA1 and anti-GFAP are not as clearly defined.
- The text reviews both the common and less common antibody-mediated myelopathies and discusses differential diagnoses that may resemble these conditions.
Article Abstract
Myelopathy is an increasingly recognized presentation of many antibody-mediated neuroinflammatory disorders. While specific features of certain autoimmune myelopathies such as aquaporin-4 antibody associated neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein associated disorder (MOGAD) are well-characterized, other less commonly seen antibody-associated myelopathies are not as well-defined. These include but are not limited to, Hu/ANNA1, anti-glial fibrillary acidic protein (GFAP), anti-CV2/collapsin response mediator protein (CRMP5), and amphiphysin. Here, we review the mentioned more common antibody mediated myelopathies as well those that as less common, followed by a review of differentials that may mimic these disorders.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366192 | PMC |
| http://dx.doi.org/10.3389/fneur.2022.972143 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Venous thromboembolism in bullous pemphigoid: current evidence and update on systematic review.
Dermatol Reports
January 2025
Dermatology, King Fahad Medical City, Riyadh.
Various studies have shown that individuals with bullous pemphigoid (BP) are more likely to develop venous thromboembolism (VTE). However, it is important to acknowledge that these studies primarily focused on individuals in Western nations, which restricts their generalization to a wider demographic. The present systematic review aims to assess the cumulative risk of VTE in individuals with BP compared to healthy individuals.
View Article and Find Full Text PDFThe Banning of Engineered Stone in Australia: An Evidence-Based and Precautionary Policy.
Int J Soc Determinants Health Health Serv
January 2025
CHU Rennes, Inserm, EHESP, Irset-Institut de Recherche en Santé, Environnement et Travail-UMRS, University of Rennes, Rennes, France.
On December 13, 2023, Australia became the first country to ban engineered stone. This material contains more than 80 percent crystalline silica, agglomerated with resins, metal oxides and other (potentially toxic) substances. Engineered stone has become a mass-market product since the late 1990s and has contributed to a worldwide resurgence of accelerated forms of silicosis and a notable incidence of systemic diseases.
View Article and Find Full Text PDFA comparative analysis of risk stratification tools in systemic sclerosis-associated pulmonary arterial hypertension: a EUSTAR analysis.
Rheumatology (Oxford)
January 2025
Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Objectives: The 2022 European Society of Cardiology and European Respiratory Society (ESC/ERS) Guidelines for pulmonary arterial hypertension (PAH) recommend risk stratification to optimize management. However, the performance of generic PAH risk stratification tools in patients with systemic sclerosis (SSc)-associated PAH remains unclear. Our objective was to identify the most accurate approach for risk stratification at SSc-PAH diagnosis.
View Article and Find Full Text PDFLysophosphatidylcholine induces ceramide synthase-2 expression in primary culture model of astrocytopathy: potential therapeutic target in multiple sclerosis.
Mol Biol Rep
January 2025
Department of Pharmacology, School of Health Sciences, Central University of Punjab, Bathinda, 151401, India.
Background: Multiple sclerosis (MS) is a chronic autoimmune condition that damages the myelin sheath of neurons in the central nervous system, resulting in compromised nerve transmission and motor impairment. The astrocytopathy is considered one of the prominent etiological factor in the pathophysiology of demyelination in MS. The expression level of ceramide synthase-2 (CS-2) is yet to be established in the pathophysiology of astrocytopathy although the derailed ceramide biosynthetic pathways is well demonstrated in the pathophysiology of demyelination.
View Article and Find Full Text PDFUpdate in Clinical Science: Autoimmune Hepatitis.
J Hepatol
January 2025
I. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Electronic address:
Autoimmune hepatitis (AIH) is an enigmatic, relatively rare disease with a variable spectrum of presentation whose pathogenesis, diagnosis and management remain a major challenge. Methods. We have performed a review incorporating recent developments in basic science, epidemiology, clinical science, therapeutics, regulatory science and evaluated the challenges associated with the application of translational research and clinical trial design to a condition that is a chameleon in nature, where outcomes range from relatively benign disease through cirrhosis and acute liver failure.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!